SI-BONE, Inc.SIBN stock score: 59/100
$23.75 · +0.89% · Scored Nov 19, 2026
- Technical
- 66
- Fundamental
- 57
- News
- 51
The reading
SI-BONE (SIBN) scores 59 out of 100, which reads neutral, higher than 71% of Healthcare stocks and 72% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 57, technicals 66.
Among the fundamentals, Quick Ratio at 100 and Current Ratio at 100 score highest, while Earnings Growth (5-Year) at 2 weighs the most against it.
On the daily chart, trend-following indicators average 64 and contrarian oscillators 48.
News sentiment is neutral at 51; it is shown, not counted in the composite.
Since Aug 23, 2026 the composite has ranged from 51 to 59, and it is up 3 points over the period.
About SI-BONE
SI-BONE (SIBN) is a medical device company that makes implants and instruments for surgery involving the sacropelvic region, where the spine connects to the pelvis. Its iFuse family of titanium implants is used to fuse the sacroiliac joint in patients with related low back pain, and it includes newer products such as iFuse INTRA Ti. Its iFuse Bedrock Granite implant is used to anchor and stabilize the pelvis in spinal fusion surgery for adult deformity and degenerative spine conditions. Its iFuse TORQ products treat pelvic fractures, and a trauma version is distributed to trauma centers by Smith+Nephew. Customers include spine, orthopedic and trauma surgeons and interventional physicians working in hospitals, surgery centers and office-based labs. SI-BONE sells mainly through its own sales force in the United States and through direct and distributor sales in Europe, and it earns money from sales of implants used in each procedure.
SI-BONE competes with Medtronic, Globus Medical, Orthofix and smaller companies such as PainTEQ. Its edge rests on clinical studies supporting its implants, a focused product line for the sacropelvic region and established relationships with surgeons. Investors who follow SIBN stock tend to watch revenue growth and the number of active surgeons using its products. Procedure volumes and reimbursement from Medicare and private insurers are closely followed. Adoption of new products, gross margins, operating expenses and progress toward sustained profitability are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward SIBN’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
57Pulling it up
- Quick Ratio100
Quick ratio measures a company's ability to meet short-term obligations with liquid assets.
Current assets divided by current liabilities: the ability to pay short-term bills.
Debt-to-Equity ratio measures financial leverage by comparing total debt to shareholder equity.
Holding it back
5-year earnings growth evaluates long-term profit trajectory and consistency.
Return on Equity (ROE) measures how efficiently a company generates profits from shareholder equity.
Operating margins measure profitability after operating expenses.
38 weighted scorers; 1 had no data today and are left out rather than counted as zero.
Technical · daily
63Pulling it up
Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.
- SMA 200100
Simple Moving Average (200-period) is the most widely followed long-term trend indicator.
Ichimoku Cloud is a comprehensive indicator showing support/resistance, trend direction, and momentum.
Holding it back
SPY SMA 20 measures the S&P 500 (SPY) position relative to its 20-period moving average.
SPY SMA 50 tracks the S&P 500 (SPY) position relative to its 50-period moving average.
SPY SMA 10 evaluates the S&P 500 (SPY) position relative to its 10-period simple moving average.
61 weighted scorers; 4 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 51
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 53 | 1 |
| Daily | 63 | 3 |
| Weekly | 69 | 2 |
| Monthly | 73 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 59 |
| Nov 18, 2026 | 58 |
| Nov 17, 2026 | 58 |
| Nov 16, 2026 | 58 |
| Nov 15, 2026 | 58 |
| Nov 14, 2026 | 58 |
| Nov 13, 2026 | 58 |
| Nov 12, 2026 | 58 |
| Nov 11, 2026 | 56 |
| Nov 10, 2026 | 56 |
| Nov 7, 2026 | 56 |
| Nov 6, 2026 | 56 |
| Nov 5, 2026 | 55 |
| Nov 4, 2026 | 57 |
| Nov 3, 2026 | 55 |
| Nov 2, 2026 | 54 |
| Nov 1, 2026 | 55 |
| Oct 30, 2026 | 55 |
| Oct 29, 2026 | 57 |
| Oct 27, 2026 | 56 |
| Oct 26, 2026 | 56 |
| Oct 25, 2026 | 56 |
| Oct 24, 2026 | 56 |
| Oct 23, 2026 | 56 |
| Oct 22, 2026 | 56 |
| Oct 21, 2026 | 57 |
| Oct 20, 2026 | 56 |
| Oct 19, 2026 | 55 |
| Oct 18, 2026 | 55 |
| Oct 17, 2026 | 55 |
| Oct 16, 2026 | 55 |
| Oct 15, 2026 | 55 |
| Oct 14, 2026 | 55 |
| Oct 13, 2026 | 55 |
| Oct 12, 2026 | 56 |
| Oct 11, 2026 | 55 |
| Oct 10, 2026 | 55 |
| Oct 9, 2026 | 55 |
| Oct 8, 2026 | 53 |
| Oct 7, 2026 | 55 |
| Oct 6, 2026 | 56 |
| Oct 5, 2026 | 56 |
| Oct 4, 2026 | 52 |
| Oct 3, 2026 | 52 |
| Oct 2, 2026 | 51 |
| Oct 1, 2026 | 52 |
| Sep 30, 2026 | 54 |
| Sep 29, 2026 | 55 |
| Sep 28, 2026 | 54 |
| Sep 27, 2026 | 54 |
| Sep 26, 2026 | 54 |
| Sep 25, 2026 | 54 |
| Sep 24, 2026 | 55 |
| Sep 23, 2026 | 55 |
| Sep 22, 2026 | 55 |
| Sep 21, 2026 | 53 |
| Sep 20, 2026 | 51 |
| Sep 19, 2026 | 51 |
| Sep 18, 2026 | 51 |
| Sep 17, 2026 | 51 |
| Sep 16, 2026 | 53 |
| Sep 15, 2026 | 53 |
| Sep 14, 2026 | 53 |
| Sep 13, 2026 | 54 |
| Sep 12, 2026 | 54 |
| Sep 11, 2026 | 54 |
| Sep 10, 2026 | 51 |
| Sep 9, 2026 | 52 |
| Sep 8, 2026 | 53 |
| Sep 7, 2026 | 52 |
| Sep 6, 2026 | 52 |
| Sep 5, 2026 | 52 |
| Sep 4, 2026 | 53 |
| Sep 2, 2026 | 55 |
| Sep 1, 2026 | 53 |
| Aug 31, 2026 | 53 |
| Aug 30, 2026 | 54 |
| Aug 29, 2026 | 54 |
| Aug 28, 2026 | 54 |
| Aug 27, 2026 | 54 |
| Aug 26, 2026 | 54 |
| Aug 25, 2026 | 54 |
| Aug 24, 2026 | 55 |
| Aug 23, 2026 | 56 |
Key facts
- Market cap
- $1.1B
- Sector
- Healthcare
- Industry
- Medical Devices
- Beta
- 0.62
- Risk grade (1–10)
- 7
- Next earnings
- Nov 2, 2026
Medical Device peers
| Company | Market cap | Score |
|---|---|---|
| NVCR NovoCure | $1.2B | 44 |
| TNDM Tandem Diabetes Care | $1.2B | 38 |
| ATEC Alphatec | $1.1B | 52 |
| IART Integra LifeSciences Holdings | $1.1B | 43 |
| IRMD IRADIMED | $1.0B | 66 |
| CBLL CeriBell | $1.0B | 51 |
Questions
What is SIBN's stock rating today?
SIBN scores 59/100 (Neutral) as of Nov 19, 2026: technical 66, fundamental 57, and news sentiment 51, which is shown but not counted. Scores are recomputed every night.
What does SI-BONE do?
SI-BONE (SIBN) is a medical device company that makes implants and instruments for surgery involving the sacropelvic region, where the spine connects to the pelvis. Its iFuse family of titanium implants is used to fuse the sacroiliac joint in patients with related low back pain, and it includes newer products such as iFuse INTRA Ti.
Is SIBN stock a buy?
The score is not a buy or sell recommendation. A 59 says the technical and fundamental signals we measure lean neutral today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the SIBN score calculated?
99 weighted scorers feed it today: 38 fundamental, scored against Healthcare ranges, and 61 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/sibn/"><img src="https://stocksscores.com/stocks/sibn/badge.svg" alt="SIBN stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/sibn/)